Promising Novel Agents in AML: The Role of Menin Inhibitors

Promising Novel Agents in AML: The Role of Menin Inhibitors

Key Findings from EHA 2024 in AML: Canadian Experts Weigh In
Icon Objectives

Learning Objectives

Upon completion of this program, participants will be able to:

  1. Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
  2. Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
  3. Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
Icon Chair Speaker

Speakers

Dr. Anna Spreafico

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

  • PHASE 1B STUDY OF AZACITIDINE, VENETOCLAX AND REVUMENIB IN NEWLY DIAGNOSED OLDER ADULTS WITH NPM1 MUTATED OR KMT2A REARRANGED AML: INTERIM RESULTS OF DOSE ESCALATION FROM THE BEATAML CONSORTIUM
  • EVOLVE-2 study
  • Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migrainethe EVOLVE-2 Study (EVOLVE-2)
  • AUGMENT-101 trial
  • KOMET-007 study
Tagged